Tavirant 200, 25, 25 mg Tablet
PDF Leaflet Revision Date: 19 September 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of adults infected with HIV-1 in combination with other antiretrovirals.
Dosage (summary)
One tablet daily with food for adults weighing at least 35 kg.
Special Populations
- Elderly patients
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; breastfeeding is contraindicated.
Key Drug Interactions
- Carbamazepine
- Rifampicin
- Proton pump inhibitors
- St. John's wort
Contraindications
- Hypersensitivity to active substances
- Co-administration with certain anticonvulsants and antimycobacterials
Common side effects
- Nausea
- Diarrhoea
- Headache
- Dizziness
- Rash
Counselling Points
- Take with food
- Use effective contraception
- Monitor for opportunistic infections
Serious warnings
- Virologic failure and resistance development
- Immune reconstitution syndrome
- Lactic acidosis risk
Important Disclaimer
The Tavirant 200, 25, 25 mg Tablet professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
